Drug Profile
Research programme: pancreatic exocrine insufficiency therapy - Novozymes/AbbVie
Alternative Names: SLV 340Latest Information Update: 01 Feb 2013
Price :
$50
*
At a glance
- Originator Novozymes A/S; Solvay
- Developer AbbVie; Novozymes A/S
- Class Pancreatic enzymes
- Mechanism of Action Amylase stimulants; Lipase stimulants; Protease stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pancreatic disorders
Most Recent Events
- 01 Aug 2012 No development reported - Preclinical for Pancreatic disorders in European Union (unspecified route)
- 31 Mar 2010 Preclinical development is ongoing in European Union
- 31 Dec 2006 Preclinical development is ongoing